TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: Incidence and correlation with ERG immunohistochemistry

Histopathology

Volumn 63, Issue 2, 2013, Pages 279-286

  Gopalan, Anuradha ^a   Leversha, Margaret A ^a   Dudas, Maria E ^a   Maschino, Alexandra C ^a   Chang, Jeremy ^a   Al Ahmadie, Hikmat A ^a   Chen, Ying Bei ^a   Tickoo, Satish K ^a   Reuter, Victor E ^a,b   Fine, Samson W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Immunohistochemistry; Prostate; TMPRSS2 ERG rearrangement; Transition zone

Indexed keywords

TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 84880716753     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12153     Document Type: Article

References (53)

1. Attard G, Clark J, Ambroisine L et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2007; 27; 253-263.
2. Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007; 31; 882-888.
3. Perner S, Demichelis F, Beroukhim R et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66; 8337-8341.
4. Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostatic adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007; 67; 7991-7995.
5. Rajput AB, Miller MA, De Luca A et al. Frequency of the TMPRSS2-ERG fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 2007; 60; 1238-1243.
6. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310; 644-648.
7. Darnel AD, LaFargue CJ, Vollmer RT, Corcos J, Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol. Ther. 2009; 8; 125-130.
8. Demichelis F, Fall K, Perner S et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26; 4596-4599.
9. Gopalan A, Leversha MA, Satagopan JM et al. TMPRSS-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res. 2009; 69; 1400-1406.
10. Mosquera JM, Mehra R, Regan MM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin. Cancer Res. 2009; 15; 4706-4711.
11. Nam RK, Sugar L, Yang W et al. Expression of TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 2007; 97; 1690-1695.
12. Soller MJ, Isaksson M, Elfving P, Soller W, Lundgren R, Panagopoulos I. Confirmation of the high frequency of TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosom. Cancer 2006; 45; 717-719.
13. Tu JJ, Rohan S, Kao J, Kitabayashi N, Mathew S, Chen YT. Gene fusion between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissue. Mod. Pathol. 2007; 20; 921-928.
14. Wang J, Cai Y, Ren C, Ittmann M et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 2006; 66; 8347-8351.
15. Toubaji A, Albadine R, Meeker AK et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod. Pathol. 2011; 24; 1511-1520.
16. Petrovics G, Liu A, Shaheduzzaman S et al. Frequent expression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005; 24; 3847-3852.
17. Fine SW, Gopalan A, Leversha MA et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod. Pathol. 2010; 23; 1325-1333.
18. Greene DR, Fitzpatrick JM, Scardino PT. Anatomy of the prostate and distribution of early prostate cancer. Semin. Surg. Oncol. 1995; 11; 9-22.
19. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J. Urol. 1991; 146; 1069-1076.
20. Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br. J. Urol. 1991; 68; 499-509.
21. Grignon DJ, Sakr WA. Zonal origin of prostatic adenocarcinoma: are there biologic differences between transition zone and peripheral zone adenocarcinomas of the prostate gland? J. Cell. Biochem. Suppl. 1994; 19; 267-269.
22. Noguchi M, Stamey TA, McNeal JE, Yemoto CE. An analysis of 148 consecutive transition zone cancers: clinical and histologic characteristics. J. Urol. 2000; 163; 1751-1755.
23. Shannon BA, McNeal JE, Cohen RJ. Transition zone carcinoma of the prostate gland: a common indolent tumour type that occasionally manifests aggressive behavior. Pathology 2003; 35; 467-471.
24. McNeal JE. Normal histology of the prostate. Am. J. Surg. Pathol. 1988; 12; 619-633.
25. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Pathol. 1992; 23; 258-266.
26. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am. J. Surg. Pathol. 1988; 12; 897-906.
27. Noel EE, Ragavan N, Walsh MJ et al. Differential gene expression in the peripheral zone compared to the transition zone of the human prostate gland. Prostate Cancer Prostatic Dis. 2008; 11; 173-180.
28. van der Heul-Nieuwenhuijsen L, Hendriksen PJ, van der Kwast TH, Jenster G. Gene expression profiling of the human prostate zones. BJU Int. 2006; 98; 886-897.
29. Al-Ahmadie HA, Tickoo SK, Olgac S et al. Anterior-predominant prostatic tumors: zone of origin and pathologic outcomes at radical prostatectomy. Am. J. Surg. Pathol. 2008; 32; 229-235.
30. Fine SW, Al-Ahmadie HA, Gopalan A, Tickoo SK, Scardino PT, Reuter VE. Anatomy of the anterior prostate and extraprostatic space: a contemporary surgical pathology analysis. Adv. Anat. Pathol. 2007; 14; 401-407.
31. Leversha MA. Mapping of genomic clones by fluorescence in situ hybridization. Methods Mol. Biol. 2001; 175; 109-127.
32. Bott SRJ, Young MPA, Kellett MJ et al. Anterior prostate cancer: is it more difficult to diagnose? BJU Int. 2002; 89; 886-889.
33. Terris MK, Freiha FS, McNeal JE, Stamey TA. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J. Urol. 1991; 146; 78-83.
34. Zakian KL, Eberhardt S, Hricak H et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging: initial results. Radiology 2003; 229; 241-247.
35. Erbersdobler A, Fritz H, Schnöger S et al. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur. Urol. 2002; 41; 40-46.
36. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer. Urology 2007; 70; 630-633.
37. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod. Pathol. 2009; 22; 866-871.
38. Bismar TA, Trpkov K. TMPRSS2-ERG gene fusion in transition zone prostate cancer. Mod. Pathol. 2010; 23; 1040-1041.
39. Falzarano SM, Navas M, Simmerman K et al. ERG rearrangement is present in a subset of transition zone prostatic tumors. Mod. Pathol. 2010; 23; 1499-1506.
40. Liu S, Yoshimoto M, Trpkov K et al. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol. Ther. 2011; 11; 562-566.
41. Braun M, Scheble VJ, Menon R et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology 2011; 58; 1028-1036.
42. Powell MS, Li R, Dai H, Sayeeduddin M, Wheeler TM, Ayala GE. Neuroanatomy of the normal prostate. Prostate 2005; 65(52-5); 7.
43. Braun M, Goltz D, Shaikhibrahim Z et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer - a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012; 15; 165-169.
44. Chaux A, Albadine R, Toubaji A et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol. 2011; 35; 1014-1020.
45. Falzarano SM, Zhou M, Carver P et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch. 2011; 49; 441-447.
46. Gopalan A, Dudas M, Leversha MA et al. Evaluation of a novel ERG antibody in prostate cancer and correlation with TMPRSS2-ERG gene rearrangement status by FISH, ACGH and ERG mRNA expression. Mod. Pathol. 2011; 24(Suppl. 1); 194A.
47. Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12; 590-598.
48. Minner S, Luebke AM, Kluth M et al. High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11483 cancers. Histopathology 2012; 61; 445-453.
49. Mehra R, Lonigro R, Brummell B et al. Antibody based detection of ERG gene fusions in prostate cancer: an immunohistochemical study comparing c- and n-terminus ERG antibodies. Mod. Pathol. 2012; 25(Suppl. 2); 240A.
50. Dobi A, Furusato B, Shaheduzzaman S et al. ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoter. Open Cancer J. 2010; 3; 101-108.
51. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: pathological features and ERG fusion status. J. Urol. 2011; 185; 489-494.
52. Garcia JJ, Al-Ahmadie HA, Gopalan A et al. Do prostatic transition zone tumors have a distinct morphology? Am. J. Surg. Pathol. 2008; 32; 1709-1714.
53. Haarer CF, Gopalan A, Tickoo SK et al. Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors. J. Urol. 2009; 182; 1337-1341.